|
|
|
|
| LEADER |
02735nam a22004815i 4500 |
| 001 |
978-3-319-17807-3 |
| 003 |
DE-He213 |
| 005 |
20151218072008.0 |
| 007 |
cr nn 008mamaa |
| 008 |
150620s2015 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319178073
|9 978-3-319-17807-3
|
| 024 |
7 |
|
|a 10.1007/978-3-319-17807-3
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Resistance of Cancer Cells to CTL-Mediated Immunotherapy
|h [electronic resource] /
|c edited by Benjamin Bonavida, Salem Chouaib.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2015.
|
| 300 |
|
|
|a XIX, 353 p. 38 illus., 27 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 7
|
| 520 |
|
|
|a This book, written by leading investigators, brings together the latest knowledge about key aspects of the most rapidly progressing fields of tumor escape and tumor resistance to CTL. Readers will benefit from a collection of outstanding surveys that cover some factors regulating resistance to CTL cytotoxicity, the influence of tumor microenvironment, and the resistance to death ligands, mediated apoptosis, and means to reverse resistance. This remarkable volume also emphasizes the future directions that may lead to the design of more innovative, refined, and integrative immunotherapies to target tumor plasticity and heterogeneity, and help to overcome the inherent limitations of current treatments. By providing a broad scope of innovative concepts in the burgeoning field of cancer biology and immunotherapy, this volume will be of exceptional interest and a valuable reference for scientists, clinicians, health professionals, and biopharmaceutical companies working in the field of cancer immunotherapy. .
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Drug resistance.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Drug Resistance.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 700 |
1 |
|
|a Bonavida, Benjamin.
|e editor.
|
| 700 |
1 |
|
|a Chouaib, Salem.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319178066
|
| 830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-5501 ;
|v 7
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-17807-3
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
